A Phase 2, Open-Label, Extension Study to Evaluate the Long- Term Safety and Efficacy of Ubenimex in Patients with Pulmonary Arterial Hypertension (WHO Group 1)

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2016 - July 31, 2018